Quinine
Antimalarial — MUSCULO-SKELETAL SYSTEM
Also known as: chinine, qualaquin, quinine bisulfate heptahydrate, quinine sulfate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Quinine is an ofp drug in the Antimalarial class catalogued in DrugCentral. It was first approved by the FDA in 2005. DrugCentral lists 7 molecular targets, including SCN1A|SCN2A|SCN3A, ABCB1 and KCNB2. Recorded indications include Chloroquine Resistant Plasmodium Falciparum Malaria and Falciparum malaria.
- Approval status: ofp (first approved 2005 by the FDA).
- Drug class: Antimalarial.
- Molecular targets: SCN1A|SCN2A|SCN3A, ABCB1, KCNB2 and SLC29A4 (7 listed in DrugCentral).
- Indications: Chloroquine Resistant Plasmodium Falciparum Malaria and Falciparum malaria.
- ATC code: M09AA72 (Quinine and derivatives).
- Molecular formula: C20H24N2O2; molecular weight 324.42 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Chloroquine Resistant Plasmodium Falciparum Malaria
- Falciparum malaria
Off-label uses (1)
- Babesiosis
Contraindications (17)
- Acute nephropathy
- Anemia due to enzyme deficiency
- Atrial fibrillation
- Atrial flutter
- Black water fever
- Congenital long QT syndrome
- Disease of liver
- End stage renal disease
- Hemolytic uremic syndrome
- Hypoglycemic disorder
- Myasthenia gravis
- Neuromuscular block, function
- Optic neuritis
- Prolonged QT interval
- Thrombocytopenic disorder
- Thrombotic thrombocytopenic purpura
- Torsades de pointes
Mechanism & targets
| Established pharmacologic class | Antimalarial |
|---|
Molecular targets (7)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Sodium channel alpha subunits; brain (Types I, II, III) | SCN1A|SCN2A|SCN3A | unknown | IC50 5.36 |
| Multidrug resistance protein 1 | ABCB1 | unknown | Ki 4.92 |
| Potassium voltage-gated channel subfamily B member 2 | KCNB2 | blocker | IC50 4.90 |
| Equilibrative nucleoside transporter 4 | SLC29A4 | inhibitor | Ki 4.57 |
| Solute carrier family 22 member 1 | SLC22A1 | unknown | IC50 4.29 |
| Hemoglobin subunit alpha | HBA1 | unknown | — |
| Potassium voltage-gated channel subfamily H member 2 | KCNH2 | unknown | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2005-08-12 | FDA | — | MUTUAL PHARM CO INC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
M09AA72 | MUSCULO-SKELETAL SYSTEM › OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM › OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM › Quinine and derivatives |
P01BC01 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › ANTIMALARIALS › Methanolquinolines |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- FDA label: G6PD · Actionable PGx
- FDA label: CYP2D6
- HCSC label: G6PD · Actionable PGx
- Swissmedic label: G6PD · Actionable PGx
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Drug abuse | 1541.1 |
| Toxicity to various agents | 438.8 |
| Sedation complication | 184.1 |
| Thrombotic microangiopathy | 178.0 |
| Labile blood pressure | 153.7 |
| Cinchonism | 126.8 |
| Blood calcium decreased | 122.0 |
| Creatinine renal clearance decreased | 121.7 |
| Renal function test abnormal | 120.1 |
| Creatinine renal clearance increased | 119.0 |
| Somatic symptom disorder | 115.6 |
| Cognitive disorder | 109.4 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Quinine is on its molecule page.
| Molecular formula | C20H24N2O2 |
|---|---|
| Molecular weight | 324.42 g/mol |
| CAS number | — |
| InChIKey | LOUPRKONTZGTKE-WZBLMQSHSA-N |
| PubChem CID | 3034034 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Quinine used for?
DrugCentral lists the following indications for Quinine: Chloroquine Resistant Plasmodium Falciparum Malaria and Falciparum malaria.
How does Quinine work?
Its molecular targets in DrugCentral include SCN1A|SCN2A|SCN3A, ABCB1, KCNB2 (blocker) and SLC29A4 (inhibitor).
When was Quinine first approved?
Quinine was first approved by the FDA in 2005.
What drug class does Quinine belong to?
Quinine is in the Antimalarial class.
What is the chemical formula of Quinine?
Quinine has the molecular formula C20H24N2O2 and a molecular weight of 324.42 g/mol.
Browse: all drugs starting with Q · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4523 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL170 — compound record and bioactivity
- PubChem CID 3034034 — chemical identifiers
- DrugBank DB00468 — drug record
- FDA UNII A7V27PHC7A — substance identity
- DailyMed: FDA labels for Quinine — current prescribing information (label search)
- UniProt P08183 (ABCB1) — target protein
- UniProt Q92953 (KCNB2) — target protein
- UniProt Q7RTT9 (SLC29A4) — target protein
- UniProt O15245 (SLC22A1) — target protein
- UniProt P69905 (HBA1) — target protein
- UniProt Q12809 (KCNH2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.